StemCell Therapy

STAMFORD, Conn., May 26, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Julie Hambleton, M.D. to the Companys Board of Directors.

We are delighted to welcome Julie to the SpringWorks Board of Directors. She is a leading oncology drug developer whose experience will further strengthen our board and provide valuable insight as we advance our diversified pipeline of targeted oncology programs in rare oncology indications, multiple myeloma and metastatic solid tumors, said Saqib Islam, Chief Executive Officer of SpringWorks Therapeutics.

Dr. Hambleton, M.D. added, I am impressed by the breadth and quality of targeted oncology programs that SpringWorks is advancing both as a monotherapy for patients with rare diseases, and as combination therapies for patients with highly prevalent cancers. SpringWorks has built leading drug development capabilities and has already demonstrated strong execution across their portfolio. I look forward to working with the team and sharing my experience to guide the current and future development programs.

Julie Hambleton, M.D. is a senior biotechnology executive with over 20 years of experience in clinical drug development from pre-clinical through Phase 4 and post-marketing studies. She has extensive experience working with regulatory agencies, including the U.S. FDA and the European Medicines Agency (EMA), and in filings of Investigational New Drug Applications (INDs), Biologics License Applications (BLAs), and Special Protocol Assessments (SPAs). Dr. Hambleton served as Senior Vice President, Chief Medical Officer, Head of Development at IDEAYA Biosciences, an oncology medicine company, until her retirement on April 30, 2020. Previously, she was Vice President, Head of U.S. Medical at Bristol-Myers Squibb, overseeing Medical & Health Economic and Outcomes Research activities in support of the Oncology, Immuno-Oncology, Specialty and Cardiovascular marketed portfolios. Previously, she served as Executive Vice President and Chief Medical Officer at Five Prime Therapeutics and Vice President, Clinical Development, at Clovis Oncology. Dr. Hambleton began her industry career at Genentech, most recently as Group Medical Director, Global Clinical Development, leading a cross-functional group conducting Phase 2 and 3 trials of Avastin. Dr. Hambleton also serves on the board of directors of IGM Biosciences, Inc., a publicly traded biotechnology company, and of Arch Oncology, a privately-held biotechnology company.

Dr. Hambleton completed her medical and hematology-oncology training at the University California, San Francisco, where she then served on faculty from 1993 to 2003. She received a B.S. from Duke University, and M.D. from Case Western Reserve University School of Medicine and was Board-certified in Hematology and Internal Medicine.

About SpringWorks TherapeuticsSpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand its portfolio. For more information, please visit http://www.springworkstx.com. Follow SpringWorks Therapeutics on social media: @SpringWorksTx and LinkedIn.

Originally posted here:
SpringWorks Therapeutics Appoints Julie Hambleton, M.D. to its Board of Directors - Citybizlist Real Estate

The emergence of COVID-19 has put a spotlight on the $258 billion biotechnology industry.

Across the globe, companies large and small are racing to develop a vaccine.

After all, an effective vaccine is the only surefire path back to normal.

And, of course, that means big profits for the first to market.

Thats why the minute a headline comes out about a new development, stock prices surge higher. TakeModerna Inc. (Nasdaq: MRNA), for example. Following a report on Monday of positive results in a test on just eight individuals, MRNA stock jumped 20%. That brings the total gains for the stock to over 150% in just two months!

You can see why biotech stocks get a bad reputation as purely speculative plays. Company profits and the fate of stock gains rest solely on the outcome of clinical trials.

But if you dig deeper, you can find companies with broad product portfolios that generate billions in sales and profits.

And the truth is that the biotech industry offers an incredible value opportunity at the moment and thats why you should act now.

Ever since peaking in mid-2015, the Nasdaq Biotechnology Index (NBI) has traded in a range that previously never surpassed its prior high.

But industry profits continued to grow over that time. And the result is that valuations have become cheap especially compared to the broader stock market.

Right now, the price-to-earnings (P/E) ratio on the biotech index is 16.5. Thats below its 10-year average of 16.9.

At the same time, the P/E ratio on the S&P 500 Index is 20.9, which is well above its own 10-year average of 15.9.

That means biotech stocks are trading at a 21% discount to the stock market when, historically, theyve traded at a premium.

And now that this sector is garnering tons of attention, investors are realizing this as well. In fact, the group is being pushed above key price levels.

Check out the chart below to see the price action Im talking about:

(Click here to view larger image.)

This chart shows the price ofiShares Trust Nasdaq Biotechnology ETF (NYSE: IBB)over the past 10 years. IBB is an exchange-traded fund (ETF) that tracks the biotech sector. And as shown by the trend line, stocks in this sector are just now staging a key breakout to new highs.

What makes this breakout even more significant is the price consolidation of the past five years. That means a powerful move higher is in the works.

Cheap valuations coupled with surging momentum make biotech stocks an excellent pick in this frothy stock market.

So act quickly and pick up shares in IBB to profit from biotechs breakout!

Best regards,

Clint Lee

Research Analyst,The Bauman Letter

See more here:
Grab This ETF to Profit From Biotech's Breakout - iShares Biotechnology - Banyan Hill Publishing

Click here to get sample of the premium reporthttps://www.quincemarketinsights.com/request-sample-60943?utm_source=campaign=Pooja/AZ

The report commences with brief information of the globalBiotechnology media, sera and reagentsmarket. This report sets the tone for the rest of the report, providing users the scope of the report. The report includes important facts and statistics on the globalBiotechnology media, sera and reagentsmarket.

A globalBiotechnology media, sera and reagentsmarket is provided in this next section. This involves market introduction and a standard product definitionBiotechnology media, sera and reagents. This section provides readers with market value and year-by-year growth. Annual growth gives readers a wider view of growth patterns during the forecast period.

The report focuses on macro-economic, demand and supply drivers, constraints, and important patterns. In order to better inform the decision-making system of clients, the impact analysis for weighted average model-based growth drivers is present in the report.

The report will be updated on a number of market opportunities, which leadingBiotechnology media, sera and reagentscompanies can benefit from, to provide readers with up-to-date information on the latest developments on the globalBiotechnology media, sera and reagentsmarket. As the healthcare sector develops continuously, it is vital forBiotechnology media, sera and reagentsmanufacturers to develop key business strategies to keep a track of current developments and trends. This section provides detailed insights into the sourcing of raw materials, supply chain, regulatory approvals, price analyses, list of distributors and cost structure.

Considering the broad spectrum of the internationalBiotechnology media, sera and reagentsmarket, QMIs report provides important insights, analysis and forecast segmentation. Data are divided into product type, method, technology and region on the globalBiotechnology media, sera and reagentsmarket. This segment-specific analysis also offers a country-specific forecast taking all key parameters of the globalBiotechnology media, sera and reagentsmarket into consideration.

The last section of the report covers the competitive landscape of the globalBiotechnology media, sera and reagentsmarket to give readers an overview of company analysis and market players. This competitive intelligence is based on the categories of suppliers throughout the entire value chain and their participation in the globalBiotechnology media, sera and reagentsmarket.

QMI is committed to providing its clients with impartial and independent solutions for market research. Each QMI report is assembled after an extensive and comprehensive research. In order to give you the most comprehensive and accurate information, we use a mix of proven and innovative methodology. Primary research, secondary research, business research, focused interviews and social media analysis are our main sources of research.

Get Scope of the actual premium reporthttps://www.quincemarketinsights.com/request-toc-60943?utm_source=campaign=Pooja/AZ

Market Segmentation:

By Type: Media Sera ReagentBy Application: Cancer Research Biopharmaceuticals Regenerative Medicine & Tissue Engineering OthersBy End-User: Biotechnology & Pharmaceutical Companies Academic Institute Research LaboratoryBy Region: North America North America, by CountryUSCanadaMexico North America, by Type North America, by Application North America, by End-User Western Europe Western Europe, by CountryGermanyUKFranceItalySpainThe NetherlandsRest of Western Europe Western Europe, by Type Western Europe, by Application Western Europe, by End-User Asia Pacific Asia Pacific, by CountryChinaIndiaJapanSouth KoreaAustraliaIndonesiaRest of Asia Pacific Asia Pacific, by Type Asia Pacific, by Application Asia Pacific, by End-User Eastern Europe Eastern Europe, by CountryRussiaTurkeyRest of Eastern Europe Eastern Europe, by Type Eastern Europe, by Application Eastern Europe, by End-User Middle East Middle East, by CountryUAESaudi ArabiaQatarIranRest of Middle East Middle East, by Type Middle East, by Application Middle East, by End-User Rest of the World Rest of the World, by CountrySouth AmericaAfrica Rest of the World, by Type Rest of the World, by Application Rest of the World, by End-User

Major Companies:

Key Players:GE Healthcare, Bio-Rad laboratories Inc., Merck KGaA (Sigma Aldrich), Sartorius AG, HiMedia Laboratories Pvt., Ltd, Lonza Group Ltd, Merck & Co., Inc.

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact Us

Quince Market InsightsAjay D. (Knowledge Partner)Office No- A109,Pune, Maharashtra 411028Phone: +91 706 672 5858/+1 208 405 2835/+91 706 672 4848Email:sales@quincemarketinsights.comWeb:www.quincemarketinsights.com

Read the rest here:
Biotechnology Media, Sera and Reagents Market Study and Future Prospect | Forecast To 2028 - Azizsalon News

Increasingly inexpensive genetic sequencing and engineering tools could upend everything from health care to fuel.

Why it matters: This bio revolution could lead to a world that is more sustainable and even extend human lifespans. But its full extent is dependent on social acceptance and carries serious risks as well.

What's happening: The scientific reaction to COVID-19 illustrates the rapid change in the biological sciences, says Michael Chui, a partner at McKinsey Global Institute (MGI). "For SARS-CoV-2, it took a matter of weeks between identifying the new disease and sequencing it, compared to months for the original SARS virus."

But the response to COVID-19 only scratches the surface of what the bio revolution may make possible.

How it works: The chief driver of these changes is the rapid drop in cost of the tools that enable us to understand and increasingly manipulate the stuff of life, including in our own bodies.

The catch: Because biology is far more regulated than the field of artificial intelligence, the speed of the bio revolution will depend not just on science, but on public attitudes. The MGI report estimates 70% of the total impact could hinge on consumer, societal, and regulatory acceptance.

The bottom line: AI gets much of the attention, but advances in biotechnology are poised to be just as momentous. Put those two fields together and they will transform the world.

Read this article:
A coming bio revolution is poised to change the world - Axios

LGC Biosearch Technologies

All of the product type and application segments of the Agricultural Biotechnology market included in the report are deeply analyzed based on CAGR, market size, and other crucial factors. The segmentation study provided by the report authors could help players and investors to make the right decisions when looking to invest in certain market segments.

The Essential Content Covered in the Agricultural Biotechnology Market Report :

* Top Key Company Profiles.* Main Business and Rival Information* SWOT Analysis and PESTEL Analysis* Production, Sales, Revenue, Price and Gross Margin* Market Share and Size

The report is a compilation of different studies, including regional analysis where leading regional Agricultural Biotechnology markets are comprehensive studied by market experts. Both developed and developing regions and countries are covered in the report for a 360-degree geographic analysis of the Agricultural Biotechnology market. The regional analysis section helps readers to become familiar with the growth patterns of important regional Agricultural Biotechnology markets. It also provides information on lucrative opportunities available in key regional Agricultural Biotechnology markets.

Ask For Discounts, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=35624&utm_source=COD&utm_medium=001

Table of Content

1 Introduction of Agricultural Biotechnology Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Agricultural Biotechnology Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Agricultural Biotechnology Market, By Deployment Model

5.1 Overview

6 Agricultural Biotechnology Market, By Solution

6.1 Overview

7 Agricultural Biotechnology Market, By Vertical

7.1 Overview

8 Agricultural Biotechnology Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Agricultural Biotechnology Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report @ https://www.verifiedmarketresearch.com/product/agricultural-biotechnology-market/?utm_source=COD&utm_medium=001

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Tags: Agricultural Biotechnology Market Size, Agricultural Biotechnology Market Trends, Agricultural Biotechnology Market Growth, Agricultural Biotechnology Market Forecast, Agricultural Biotechnology Market Analysis NMK, Majhi Naukri, Sarkari Naukri, Sarkari Result

Our Trending Reports

Mobile Data Protection Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Activated Carbon Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Visit link:
Agricultural Biotechnology Market 2020 Global Overview, Growth, Size, Opportunities, Trends, Leading Company Analysis and Forecast to 2026 - Cole of...

Two companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants.

In contrast to all current vaccination approaches against SARS-Co-V-2, the approach of Mirror Biologics Inc., the US subsidiary of Jerusalem-based Immunovative Therapies Ltd., addresses the phenomenon of viral evolution. In the Journal of Translational Medicine, Michael Har-Noy and collegues describe the companies technical rationale for development of a universal anti-viral vaccine designed to protect immunocompromised humans and eldery adults from COVID-19 and any future novel virus outbreaks.

The patent-pending technology called AlloPriming is designed so that a series of injections of bioengineered Th1-cells, called AlloStim, could provide protection from any future viral infection, including progression of the current outbreak of COVID-19 infection, and any future variants of the causative SARS-CoV-2 virus or the next Disease X. The technology primes the elderly immune system to respond to viruses in the same manner as a healthy younger adult immune system would respond it remodels the aging immune system in order to reverse immunosenescence and protect against chronic inflammations. A Phase I/II clinical protocol has been prepared for testing this concept in healthy adults over 50 years in age and is currently under review by the US FDA.

The major focus for vaccine development against viruses are currently strategies that introduce inactivated whole viruses, or pieces of viruses, or viral genetic material to teach the immune system to make antibodies, which bind to the virus. The aim is to elicit antibodies which neutralize the virus by blocking entry into host cells. According to the authors, allo-priming, which triggers call-based immunity, provides a back-up in case vaccination strategies to elicit neutralising antibody protection fails or fails to protect the vulnerable elderly population.

Allo-priming is performed using activated, intentionally mismatched, ex vivo differentiated and expanded living Th1-like cells (AlloStim) derived from healthy donors. Preclinically, multiple intradermal injections of AlloStimcreated a dominate titer of allo-specific Th1/CD8-T-cytotoxic memory cells in circulation, replacing the dominance of exhausted memory cells of the aged immune system. Upon viral encounter, by-stander activation of the allo-specific memory cells caused an immediate release of interferon gamma (IFN-), stopping viral transcription and leading to by-stander activation of innate cellular effector cells and activation of cross-reactive allo-specific CD8-T-cytotoxic lymphocytes.

A youthful immune response is believed to be most capable of clearance of viral infections before the infection progresses to serious disease", said Reuven or, who co-authored the publication. He sees the approach as complementary to current vaccination approaches. But in deed it is more:

All current vaccination approaches have not been successful in protecting against emergent viruses, such as HIV, hepatitis C, Zika, dengue and the pandemic SARS and MERS coronaviruses, which mutatate and adapt very rapidly to its hosts. In contrast to childhood diseases they will not provide lifelong protection because they are based on an approach viral evolution, which does not occur in pathogens such as measles or other childhood diseases. For this reason, current vaccine technology platforms may not timely produce a protective vaccine against COVID-19 or could result in a vaccine that becomes obsolete after a viral mutation.

What is currently widely ignored: traditional vaccines could make rapidly mutating and adapting pathogens more aggressive. Under normal conditions, viral pathogens never become extremely deadly because they only spread if most of their hosts survive the infection. As vaccines create a selection advantage for viruses, which could enter and reproduce themselves ultrarapidly in the host cell, they might trigger a kind of vaccine-driven evolution, which would make viruses more deadly and devasting as postulated for the case of Marek's disease vaccines a neoplastic disease of poultry.

Lead author Michael Har-Noy commented: "While there is great optimism regarding current clinical trials investigating protective vaccines against COVID-19, there is a very real possibility that none of the vaccine candidates under investigation will prove to provide long-term protection from COVID-19, and some vaccine candidates may even make symptoms worse. Even in the event that an effective vaccine is timely developed, such a vaccine likely would not be as effective in providing protective immunity in the elderly. If allo-priming is proven to work as designed, a single series of shots could protect against the current pandemic as well as any future pandemic.

The rest is here:
Vaccine to protect from any viral infection - European Biotechnology

Shire

All of the product type and application segments of the Nanoparticles in Biotechnology and Pharmaceuticals market included in the report are deeply analyzed based on CAGR, market size, and other crucial factors. The segmentation study provided by the report authors could help players and investors to make the right decisions when looking to invest in certain market segments.

The Essential Content Covered in the Nanoparticles in Biotechnology and Pharmaceuticals Market Report :

* Top Key Company Profiles.* Main Business and Rival Information* SWOT Analysis and PESTEL Analysis* Production, Sales, Revenue, Price and Gross Margin* Market Share and Size

The report is a compilation of different studies, including regional analysis where leading regional Nanoparticles in Biotechnology and Pharmaceuticals markets are comprehensive studied by market experts. Both developed and developing regions and countries are covered in the report for a 360-degree geographic analysis of the Nanoparticles in Biotechnology and Pharmaceuticals market. The regional analysis section helps readers to become familiar with the growth patterns of important regional Nanoparticles in Biotechnology and Pharmaceuticals markets. It also provides information on lucrative opportunities available in key regional Nanoparticles in Biotechnology and Pharmaceuticals markets.

Ask For Discounts, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=COD&utm_medium=001

Table of Content

1 Introduction of Nanoparticles in Biotechnology and Pharmaceuticals Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Nanoparticles in Biotechnology and Pharmaceuticals Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Deployment Model

5.1 Overview

6 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Solution

6.1 Overview

7 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Vertical

7.1 Overview

8 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=COD&utm_medium=001

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Tags: Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Trends, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Nanoparticles in Biotechnology and Pharmaceuticals Market Forecast, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis NMK, Majhi Naukri, Sarkari Naukri, Sarkari Result

Our Trending Reports

Nanomagnetic Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

More:
Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Global Overview, Growth, Size, Opportunities, Trends, Leading Company Analysis and...

A perfect mix of quantitative & qualitative Agriculture Biotechnologymarket information highlighting developments, industry challenges that competitors are facing along with gaps and opportunities available and would trend in Agriculture Biotechnologymarket. The study bridges the historical data from 2014 to 2019 and estimated until 2025.

The Agriculture BiotechnologyMarket report also provides the market impact and new opportunities created due to the COVID19/CORONA Virus Catastrophe The total market is further divided by company, by country, and by application/types for the competitive landscape analysis. The report then estimates 2020-2025 market development trends of Agriculture BiotechnologyIndustry.

Downlaod Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6319455/agriculture-biotechnology-market

The Top players are ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury Transgene, Certis, Dow AgroSciences, Eurofins, Evogene, Global Bio-chem Technology, Syngenta, KWS Saat, Marina Biotech, Monsanto, .

Market Segmentation:

On the basis of the end users/applications, Transgenic crops market, Synthetic biology-enabled products market

Download Free Sample PDF along with few company profileshttps://inforgrowth.com/sample-request/6319455/agriculture-biotechnology-market

Be the first to knock the door showing the potential that Agriculture Biotechnologymarket is holding in it. Uncover the Gaps and Opportunities to derive the most relevant insights from our research document to gain market size.

A major chunk of this Global Agriculture BiotechnologyMarket research report is talking about some significant approaches for enhancing the performance of the companies. Marketing strategies and different channels have been listed here. Collectively, it gives more focus on changing rules, regulations, and policies of governments. It will help to both established and new startups of the market.

The study objectives of this report are:To analyze global Agriculture Biotechnologystatus, future forecast, growth opportunity, key market, and key players.To present the Agriculture Biotechnologydevelopment in the United States, Europe, and China.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by product type, market, and key regions.

Get Special Discount Up To 50%, https://inforgrowth.com/discount/6319455/agriculture-biotechnology-market

Major Points from Table of Contents

1 Agriculture Biotechnology Agriculture Biotechnology Market Overview2 Agriculture Biotechnology Market Competition by Manufacturers3 Production Capacity by Region4 Global Agriculture Biotechnology Market by Regions5 Production, Revenue, Price Trend by Type6 Global Agriculture Biotechnology Market Analysis by Application7 Company Profiles and Key Figures in Agriculture Biotechnology Business8 Agriculture Biotechnology Manufacturing Cost Analysis9 Marketing Channel, Distributors and Customers10 Market Dynamics11 Production and Supply Forecast12 Consumption and Demand Forecast13 Forecast by Type and by Application (2021-2026)14 Research Finding and Conclusion15 Methodology and Data Source.

ENQUIRE MORE ABOUT THIS REPORT AT https://inforgrowth.com/enquiry/6319455/agriculture-biotechnology-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

Go here to see the original:
Agriculture Biotechnology Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top...

Global Biotechnology Reagents Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.

Biotechnology Reagents Market Size Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast And Business Opportunity.

>>Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=12804&RequestType=Sample

Global Biotechnology Reagents Market is valued at USD 71.25 Billion in 2018 and expected to reach USD 121.06 Billion by 2025 with the CAGR of 7.86% over the forecast period.

Increasing prevalence of diseases such as hepatitis B with growing research and development expenditure bybiotechnologytherapeutics and rising number of biotechnology firms globally are expected to boost the market over the forecast period.

Biotechnology reagents are the substances or compounds used to detect or create an additional substance in order to provide a test reading. Hence, the biotechnologies are used in research fields of genetics, molecular biology, diagnosis, immunology, bioscience and in education. The various uses of biotechnology reagents are; fluorescent microscopy, DNA analysis, immuno phenotyping and cell cycle analysis. The biotechnology reagents industry depends on the growth of biotechnology instrumentation market. Biotechnology reagents market includes technologies such as IVD, PCR, transfection, gene expression and cell culture. The basis of technology market is section into analytical reagents and life science reagents. The Life science technologies include in vitro diagnostics, unit culture, polymerase chain reaction and analytical technologies includes flow cytometry, electrophoresis, mass spectrometry and chromatography. The healthcare biotechnology is usually to improve medicines due to the advantages and pieces of knowledge it provides such as understanding the genetic composition of the human species, foundational structure of hereditary diseases manipulation and repairing of damaged genes to cure diseases. As the researchers might see the engineering of a supercharged flu virus as a perfectly reasonable way to better understand and thus fight the flu, the public might see the drawbacks as equally obvious the virus could escape, or someone could weaponize the research and the advanced genetic tools that some are considering for mosquito control could have unforeseen effects, possibly leading to environmental damage. Although the risks of biotechnology have been fretted over for decades, the increasing pace of progress from low cost DNA sequencing to rapid gene synthesis to precision genome editing suggests biotechnology is entering a new realm of maturity regarding both beneficial relevance and more worrisome risks.

Global Biotechnology Reagents Market report is segmented on the basis of type, application, and by regional & country level. Based on type, global biotechnology reagents market is classified as the Life science and analytical. Based upon application, global biotechnology reagents are classified into protein synthesis and purification, gene expression, DNA and RNA analysis and drug testing.

The regions covered in this biotechnology reagents market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of biotechnology reagents is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Biotechnology Reagents Market Report-

Some major key players for Global Biotechnology Reagents Market are Life Technologies, Bio-Rad, Thermo Fisher Scientific, Water Corporation, Sigma-Aldrich Agilent Technologies Inc., Beckman Coulter, Roche, Abbott and others.

Global Biotechnology Reagents Market Dynamics

The rapidly increasing use of biotechnology reagents in therapeutics, basic research and its commercialization are the major factors responsible for the growth of this market. According to the World Health Organization (WHO) in 2017, prevalence of hepatitis B estimated about 27 million people 10.5% of all people estimated to be living with hepatitis B were aware of their infection, while 4.5 million around 16.7% of the people diagnosed were on treatment. Hence, the rising prices of DNA sequencing is predictable to serve this sector as a high impact rendering growth is expected to encourage researchers and manufacturers to increase R&D initiatives targeted at understanding genetic variations and developing therapeutic solutions for chronic diseases with large global prevalence such as cardiovascular diseases, diabetes, and cancer. According to the World Health Organization (WHO) in 2015, the estimates that in 257 million people were living with chronic hepatitis B infection as surface antigen positive, the hepatitis B resulted in an estimated 887 000 deaths, mostly from cirrhosis and hepatocellular carcinoma is primary liver cancer. In addition, the high investments in R&D activities, growing biomedical research, increasing number of biotechnology firms and advancement in stem cell research have contributed to the growth of the biotechnology reagents market.

The biotechnology organizations such as the department of biotechnology (DBT) with government funded institutions and other autonomous organizations representing the biotechnology sector, promote funding to support R&D and innovative produce development endeavors. One of the major challenges faced by this market use of biotechnology reagents in the field of drug discovery is an emerging market where proteomics, DNA chips, combinatorial chemistry, and high throughput screening enjoy the spotlight. In addition, high price of biopharmaceuticals may likely to restrain the growth of the biotechnology reagents market. Moreover, increase in the number of biotechnology firms around the globe and increase in research and development expenditure by the biotechnology corporation can provide various opportunities for the further growth of the market. The technological advancements and new product launches in health care and life science industries to life science reagents are an integral part of any clinical diagnostic laboratory and pharmaceutical & biotechnology industry. The recent technological advancements in molecular biology, life sciences, and biotechnology has brought about drastic changes in various fields such as medical diagnostics, drug discovery, personalized medicines, forensic sciences, and clinical research & development of the biotechnology reagents market.

Global Biotechnology Reagents Market Regional Analysis

Geographically,North America dominates the global biotechnology reagents market & incurs the highest expenditure for global R&D. According to the World Health Organization (WHO) in 2018, the chronic diseases in the United States are about 133 million Americans 45% of the population have at least one chronic disease. In addition, rising ongoing research in biological sciences considerable investments by various biotechnology companies and the consistently increasing utilization of biotechnology reagents in the market due to the continuing research and outsourcing activities in the field of life science in this region are also supplementing the market growth.

TheAsia Pacific is expected to show a lucrative growth rate during the forecast period due to increasing research and outsourcing activities in life science field. However, the regionlarge population, presence of emerging economies such as China and India, large number of elderly individuals in Japan presents significant opportunities for global players in these countries. Adoption of technologically advanced products in Japan, China, South Korea, Malaysia, and Singapore are likely to fuel the growth of the life science reagents market in this region. Moreover, increased investment by leading pharmaceutical and biotechnology companies in India and China, and rapidly increasing number of hospitals and diagnostic laboratories in the region boost the growth of the biotechnology reagents market in the region.

Key Benefits for Global Biotechnology Reagents Market Report

Global market report covers in depth historical and forecast analysis.

Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.

Global market report helps to identify opportunities in market place.

Global market report covers extensive analysis of emerging trends and competitive landscape.

By Type

By Application

By Regional & Country Analysis

Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=12804&RequestType=Methodology

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the Global Biotechnology Reagents Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Global Biotechnology Reagents Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the Global Biotechnology Reagents Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global Biotechnology Reagents Market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global Biotechnology Reagents Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the Global Biotechnology Reagents Market.

Market Forecast: Here, the report offers a complete forecast of the Global Biotechnology Reagents Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Excerpt from:
COVID 19 PANDEMIC: Biotechnology Reagents Market is poised to achieve continuing growth During Forecast Period 2020-2026 - Cole of Duty

A rating of 9 puts Therapix Biosciences Ltd - ADR (TRPX) near the bottom of the Biotechnology industry according to InvestorsObserver. Therapix Biosciences Ltd - ADR's score of 9 means it scores higher than 9% of stocks in the industry. Therapix Biosciences Ltd - ADR also received an overall rating of 22, putting it above 22% of all stocks. Biotechnology is ranked 10 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 22 would rank higher than 22 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Therapix Biosciences Ltd - ADR (TRPX) stock is down -2.31% while the S&P 500 is up 0.05% as of 11:03 AM on Tuesday, May 19. TRPX is lower by -$0.01 from the previous closing price of $0.42 on volume of 654,488 shares. Over the past year the S&P 500 has gained 4.05% while TRPX is lower by -87.27%. TRPX lost -$2.40 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Read more:
Where Does Therapix Biosciences Ltd - ADR (TRPX) Stock Fall in the Biotechnology Field? - InvestorsObserver

PHOENIX--(BUSINESS WIRE)-- BioLab, Inc., a regenerative biotechnology company, today announced a partnership with Red One Medical that will help veterans and active military members access breakthrough wound healing and regenerative medicine.

Red One Medical is private sector innovation partner of Department of Veterans Affairs (VA) and Department of Defense (DoD) hospitals. As a Service-Disabled Veteran-Owned Small Business (SDVOSB), it provides advanced medical and pharmaceutical technologies that improve patient care for America's military veterans. BioLab Sciences is working with Red One Medical to distribute regenerative medicine products and MyOwn Skin, a novel biotechnology that can accelerate the healing of severe burns, chronic wounds, diabetic foot ulcers, and other difficult-to-heal wounds.

Nearly one in four veterans has diabetes, and as such, the need for an innovative wound care solution is critical to treat non-healing diabetic ulcersthe leading cause of lower-limb amputations in non-combat veterans.

Were constantly on the lookout for innovative products to speed wound healing in veteran and military hospitals," said Red One Medical CEO and Founder Charles Pollak. "We want our veterans to receive top quality care, and MyOwn Skin takes wound care to the next level by leveraging a patient's own skin to quickly grow skin grafts in a new, non-invasive way."

MyOwn Skin leverages a very small sample of a patient's skin and blood taken through a non-surgical procedure to reproduce three, 100cm2 skin grafts within a week. MyOwn Skin eliminates the need for traditional skin grafts which require surgical procedures to remove large areas of healthy skin from other parts of a patients body, often resulting in additional wounds requiring care and healing time.

We are on a mission to help patients and providers access regenerative medicine products that help the body achieve optimal performance, said BioLab Sciences President and CEO Bob Maguire. As the VAs private sector innovation partner, Red One Medical is in a unique position to help advance the delivery of care to our nations veteran and military patients. This partnership is one step forward in that direction.

Along with MyOwn Skin, which is now one of the most advanced products in Red One Medical's wound care portfolio, the company will also distribute BioLab Sciences amniotic allograft membrane, amniotic liquid allograft and other regenerative products that promote healing for wound, orthopedic, respiratory and ophthalmic care. The products will be available to the DoD and VA health system, which includes more than 9 million veterans at approximately 1,700 facilities.

About BioLab Sciences

BioLab Sciences is a regenerative medicine company focused on creating new ways to heal the body. Headquartered in Scottsdale, Arizona, BioLab Sciences is uncovering better ways to address orthopedic injuries, wound care, pain management, aesthetic medicine, respiratory ailments, cardiovascular indications, ophthalmic issues, and more. BioLab Sciences is transforming wound care through MyOwn Skin, a remarkable biotechnology that leverages a small sample of a patient's own skin from a non-surgical procedure to produce up to three 4-inch x 4-inch skin grafts in a week. Learn more at http://www.biolabsciences.net/.

About Red One Medical

Red One Medical is a private sector innovation partner of Department of Veterans Affairs (VA) medical centers and Department of Defense (DoD) hospitals. Red One Medical identifies and delivers advanced medical and pharmaceutical technologies that transform care for Americas military veterans. Located in Savannah, GA, Red One Medical is a CVE-certified Service Disabled Veteran Owned Business (SDVOSB) and SBA-certified Historically Underutilized Business Zone (HUBZone) company. It donates a portion of profits to charities that support veterans, military families and their communities.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005189/en/

See more here:
BioLab Sciences Partners with Red One Medical to Provide Transformative Wound Healing Products to Veterans and Active Military - BioSpace

The research report on Biotechnology Separation Systems market is a comprehensive analysis of this business space and entails all the key aspects of the industry including net revenue estimates, present renumeration, periodic deliverables, segmental share, market size, and market trends.

A brief assessment of the behavior pattern of the Biotechnology Separation Systems market over the forecast timeline has been cited in the report. Critical parameters such as growth drivers as well the expected growth rate followed during the study period are also documented in the report. It further elaborates on the potential growth aspects and restraints of this industry.

Main highlights of Biotechnology Separation Systems market report:

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/65717

Geographical scrutiny of the Biotechnology Separation Systems market:

Biotechnology Separation Systems Market Segmentation: USA, Europe, Japan, China, India, South East Asia.

Key insights presented in the report with respect to the regional outlook:

A thorough analysis of Biotechnology Separation Systems market with respect to the product landscape and application spectrum:

Product landscape:

Product types:

Application landscape:

Other takeaways of Biotechnology Separation Systems market report:

Additional insight on the competitive outlook of the Biotechnology Separation Systems market:

Vendor base of the industry:

Vital parameters which define the competitive landscape of the Biotechnology Separation Systems market:

The study objectives are:

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/65717

More:
Biotechnology Separation Systems Market: Worldwide Industry to Boost in the Period of 2020-2025 - Express Journal

The main objective of this research report is to present the comprehensive analysis about the factors which are responsible for the growth of the global Plant Derived Protein market. The study report covers all the recent developments and innovations in the market for a Plant Derived Protein. There are many government bodies, regulatory associations and universities are extending their help in the form of funds, investments and grants to promote research into the development of products of global Plant Derived Protein market. These activities of researching and funding are fuelling to the development of innovative products.

This study covers following key players:MedicagoPlanet BiotechnologyVentria BiosciencePromoCellKentucky BioprocessingAgrenvecAxol Bioscience

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4555103?utm_source=Pooja

Furthermore, Report provides the deep analysis about the impact of domestic and global players on market, trade regulation, value chain optimization, and opportunities analysis for new present as well as new players, recent developments, strategic market growth analysis, area marketplace expanding, product launches, technological innovations and many more. The study report of global Plant Derived Protein market can be split on the basis of key segments such as product type, application, key companies and key regions. Also the growth of the global Plant Derived Protein market can be projected on the basis of segments and calculation for sales by application and type of the product in terms of volume and value.

In addition, some essential tool which are needed for any market movements are stated in the report. SWOT and value chain rule analysis are studied for the global Plant Derived Protein market report. The global Plant Derived Protein market can be split on the basis of key segments such as type of the product, application, end users, key companies and key regions or countries. Report covers all the major regions and countries on the basis of product type and application. Key regions are mentioned in this report which are likely to grow at the highest CAGR over the forecast period. Report also presents the leading players which are functioning in global Plant Derived Protein market industry. Companies are presented with their company profile and their sales analysis in various regions and countries. Also report offer the growth strategies being implemented by these major large and small market players.

Access Complete Report @ https://www.orbisresearch.com/reports/index/global-plant-derived-protein-market-growth-2020-2025?utm_source=Pooja

Market segment by Type, the product can be split into Protein PolymersTherapeutic ProteinsCell Culture Functional ProteinsOthersMarket segment by Application, split into Biopharmaceutical CompanyAcademic & Research InstituteContract Research OrganizationOthers

This report provides customers with market statistics by studying the historic data and current status of the market. Also report ensures the success of user by providing comprehensive study of the market. The database is constantly updated in order to fulfil the demands of the clients. Thus report consist of a comprehensive variety of information from key industry. Report offers in depth insight on global products, industries and market trends for the customers.

Some TOC Points:

1 Industry Overview of Plant Derived Protein2 Major Manufacturers Analysis of Plant Derived Protein3 Global Price, Sales and Revenue Analysis of Plant Derived Protein by Regions, Manufacturers, Types and ApplicationsContinued

For Enquiry before buying report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4555103?utm_source=Pooja

Some TOC Points:1 Scope of the Report2 Executive Summary3 Global Plant Derived Protein by Company4 Plant Derived Protein by RegionsContinued

About Us:Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

Continued here:
Global Plant Derived Protein Market anticipated grow at a CAGR of xx% over the forecast period 2020-2025 :Medicago, Planet Biotechnology, Ventria...

Written by Seema Chishti | New Delhi | Updated: April 26, 2020 11:22:47 am Dr Renu Swarup, Secretary, Department of Biotechnology.

The Department of Biotechnology, under the Ministry of Science And Technology, is the nodal point for all the science-based solutions India is looking for in the battle against COVID-19. Dr Renu Swarup, Secretary, Department of Biotechnology, speaks to The Indian Express on the road ahead.

What role is the Department of Biotechnology (DBT) playing on a day-to-day basis as India wades through this crisis?

Call it day-to-day, hour-to-hour or minute-to-minute. DBT is central to all the science around COVID. Healthcare solutions, diagnostics, vaccines or therapeutics, we are the nodal agency, and this is not just about funding. COVID has set a very clear example of how the government is looking at science and its role of facilitation. We are bringing the countrys scientists on various platforms, institutions, clearing regulatory pathways. We enable coordination. BIRAC (Biotechnology Industry Research Investment Council) has been central to assisting start-ups and connecting them to investors and investments. Now, with the economic crisis, start-ups are facing more challenges and our role has become more critical.

There are 16 proposals under consideration for vaccines, diagnostics and other COVID-related solutions. Could you elaborate on them?

We invited proposals and received about 500 so far, for all aspects of managing diagnostics, therapeutics, vaccines and other resources. There are two proposals which will look at vaccines. We are continuing to screen other proposals. There are 16 in the first tranche that has been cleared. They include plasma therapy models, proposals for vaccines.

Anything more on indigenous testing?

DBT has supported a number of start-ups and research groups. Two of our indigenous start-ups are now approved for manufacturing PCR kits, and in addition, a number of them are developing Rapid Antibody Tests. We have supported a national manufacturing facility at AMTZ (Andhra Pradesh Medtech Zone) Visakhapatnam for kits and ventilators.

There are only two sequences of the virus that India has shared with the worlds database?

We have shared about nine sequences with the world database. Large scale sequencing efforts are starting now. Currently we have no conclusions about what we have in India and if the virus has mutated, but ICMR is looking into it, we are using the global data of thousands of sequences.

Work is happening in Delhi and Hyderabad on genome sequencing of Sars-Cov-2. CCMB Hyderabad and IGIB New Delhi first started working together to study the sequencing?

Those institutes apart, there are six other DBT institutes involved in the work. National Institute of Biomedical Genomics (NIBMG) in Kalyani (near Kolkata), Institute for Stem Cell Science and Regenerative Medicine (inStem), Bengaluru, Institute of Life Sciences, Bhubaneswar (ILS) and Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram (RGCB) are playing a key role along with CCMB in Hyderabad and IGIB in New Delhi in the sequencing of the genome of Sars-Cov-2.

In terms of opening the lockdown, what do you see when you look ahead?

That comes under the remit of the Health Ministry, I have nothing to say.

On a different note, where is Genome India currently?

Collection of samples is not happening at the moment. But all other work in the laboratories, in the planning, computational models, continues as before.

Genome Indias second stage was meant to be collecting samples from the population which are disease-based. Any changes to that plan, a bid to fast-track the disease-based collections now, in the wake of COVID?

No, nothing yet. We will get there as we had planned.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest India News, download Indian Express App.

The Indian Express (P) Ltd

Go here to see the original:
COVID has set example of how govt is looking at science, its role of facilitation - The Indian Express

iNtRON Biotechnology, Inc. (KOSDAQ:048530) shareholders should be happy to see the share price up 13% in the last month. But over the last half decade, the stock has not performed well. In fact, the share price is down 34%, which falls well short of the return you could get by buying an index fund.

View our latest analysis for iNtRON Biotechnology

Given that iNtRON Biotechnology didnt make a profit in the last twelve months, well focus on revenue growth to form a quick view of its business development. When a company doesnt make profits, wed generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

While the broader market lost about 11% in the twelve months, iNtRON Biotechnology shareholders did even worse, losing 33%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case theres a good opportunity. Unfortunately, last years performance may indicate unresolved challenges, given that it was worse than the annualised loss of 8.1% over the last half decade. We realise that Baron Rothschild has said investors should buy when there is blood on the streets, but we caution that investors should first be sure they are buying a high quality business. Its always interesting to track share price performance over the longer term. But to understand iNtRON Biotechnology better, we need to consider many other factors. Take risks, for example iNtRON Biotechnology has 2 warning signs we think you should be aware of.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on KR exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

See the article here:
Introducing iNtRON Biotechnology (KOSDAQ:048530), The Stock That Dropped 34% In The Last Five Years - Simply Wall St

Its a great moment for big food, big ag, and industry to do a self reflection and analysis of, how did we arrive here? How did we arrive to a world where the folks that picked the produce out of the field dont have access and or make enough to buy the very produce that theyre picking? Rolando Perez, graduate student and volunteer at Xinampa

Biotechnology is on the precipice of changing our world forever. Using solutions always there in biology and optimizing them with technology, biotech promises to solve global issues such as carbon emissions, plastic and chemical pollution, and, of course, feeding a booming population. But to really solve the issue of food, the industry needs to revolutionize more than just biology or technology. It needs to revolutionize the way it engages local cultures and economies. It will not be an easy task, a straightforward task, or a quick task. But it can be done and the people of the world depend on it being done right.

Climate change and population growth have led to predictions that the global population will reach nearly 10 billion people by 2050. Current food production processes cant keep pace with that growth. Fearing an existential crisis, several companies have adopted a tag line that goes something like this: we will feed the world through innovative biotechnologies that are more sustainable and make healthy food more accessible. And theyve got the sustainability beat down: from leveraging microbes to feed plants and reduce toxic nitrogen run-off to improved aquaculture techniques to genetic engineering foods to be more nutritious, the possibilities for producing ever more nutritious food while using less of the Earths precious resources are boundless and already in motion.

But what, exactly, does it mean for food to be accessible in todays world?

Food desert a term used to describe areas with limited access to affordable and nutritious food is the label by which weve come to describe food accessibility today. But the term is a bit of a misnomer, says Garrett Broad, author of More Than Just Food.

It suggests theres nothing there and if food deserts are the problem, the solution sounds pretty simple: just bring [stuff] to the desert.

But is there really nothing there? According to a recent New York Times exposition on the obesity epidemic in Brazil (and in big industrys role in that), there are now more obese people in the world than underweight people. Its as if the pendulum has swung the other direction where hunger was once a very real problem as a result of access to food, period, now obesity, diabetes, and heart disease prevail as a result of access to high calorie, nutrient-poor foods. This has created a new type of malnutrition, write Andrew Jacobs and Matt Richtel, one in which a growing number of people are both overweight and undernourished.

So, continues Broad, the problem isnt food deserts [per se], the problem is really a legacy and generational disinvestment in and direct discrimination in not just food but in a variety of other arenas. [This] calls for a broader set of solutions.

Said another way, the issue of food accessibility is multi-faceted and therefore cannot be solved solely through biotechnology we must come to terms with that fact at the get go. That isnt to say biotechnology cant make the food production system as a whole better. With advances in gene editing and other technologies, we can use technology to improve the nutritional profile of food (tackling malnutrition), to enable seasonable crops to be available all year round (increasing accessibility in one sense), to remove undesired characteristics such as cherry pits (increasing accessibility in another sense), and to make food more resistant to drought, one of the biggest factors influencing a significant proportion of the world populations access to food. But none of this matters if we keep operating under our current system, which, according to Broad, bottom-lines on profit margins, not on feeding people healthily and sustainably.

The biotechnological revolution can give the food industry and low-income disadvantaged communities a chance to hit the reset button to learn from the current state of affairs and prevent the inevitable shortfall of the big promises being made by biotechnology today if we dont change the societal, political, and economic backbone of the way food is made and distributed. And according to Ana Ibarra and Rolando Perez, volunteers at Salinas Valley-based Xinampa (a bio-hub aiming to support equitable economic development, workforce development, small business incubation, and scientific literacy and education), such sea change will come from getting people from all walks of life to sit down together and talk.

From left: Steven Rhyans, Anna Ibarra-Castro, Leo Tejeda, Omar Perez, Matias Kaplan, Rolando Perez. Photo credit: Steven Rhyans

Many of the communities most affected by food inequality are disadvantaged, underrepresented cultural and ethic groups, such as the Hispanic/Latinx and indigenous populations served by Xinampa. Salinas, California, where Xinampa is based, is over 75% Hispanic or Latinx and it is this population that is the life blood of one of the richest agricultural areas in the world. Xinampa is especially passionate about teaching young people high school and college students how they can use biotechnology in their future careers and to bolster their local communities. Ibarra says that young people will be critical for speeding up the development of technologies, a crucial goal given the issues we have at a global scale to sustain human life in light of climate change, decreasing arable land. The younger generations have the ability and talent to carry this forward, she says, and I believe its crucial to start engagement at a young age.

But, Perez is careful to point out, it isnt just about reaching the young.

The work here is intergenerational, and thats really important. There has to be engagement across the whole intergenerational spectrum the bio belt could be about finding opportunities for retirees to do things in the community plant gardens that produce nutritious produce for the community, for example. The next generation is like the seventh generation. You can say seven generations in the future, seven generations in the past, or you can strategically place yourself in the middle of those seven generations; something I learned from a close friend and that has helped me understand my role as a community member and citizen of our planet.

Emphasizing culture and recognizing that the community as a whole, and in particular indigenous communities, has deep-seeded, critical knowledge about agriculture is a core value of Xinampa. Instead of feeding people the all-too-often heard script of you guys just dont know anything, youre eating unhealthy, and were here to change you, they recognize and encourage the generations of knowledge and cultural richness that will be critical for effectively governing and incorporating biotechnology into our future food systems.

What the most successful groups that work around food at the grassroots level do is they push past those scripts, and they open up some storytelling about peoples cultural histories through food, says Broad, and that allows folks to claim knowledge about food and cooking and agriculture, which makes them much more likely to have ownership in this whole conversation.

And the whole conversation must also engage policy makers, those involved in the public health care system, industry leaders essentially anyone that could be affected by biotechnology.

One of the solutions that we could employ to address these inequities is to look to the expertise of individuals in public health, policy, social welfare, or other disciplines that are exposed to issues through a different lens and can provide a different point of view, says Ibarra, adding that its important to foster interdisciplinary conversation early on. We dont want to miss something. We dont want to invest in a solution that may not be the most effective simply because you forgot to include someone in the conversation. Early engagement is how these nutritious and novel foods will be cultivated from the ground up for the benefit of everyone in society.

One of the reasons early involvement in conversation will enable effective distribution of food to everyone is rooted in money. According to Broad, one of the biggest reasons why mistrust in GMOs and how GMO foods could solve some big problems isnt because companies havent been transparent. Its because people look at the big players, the companies in charge, and see companies that havent made their lives substantively better. People recognize that priorities within the biotech industry have not necessarily always been first and foremost about feeding the world equitably and sustainably but instead about who profits from certain biotechnological developments, says Broad. This erodes trust rather than building it.

A great way to build long standing trust is to have equitable distribution of the material wealth that gets created from these innovations. Essentially, how do we think about the development of these tools in an equitable and inclusive way in terms of economic development and economic opportunity? The best way to do this is to get people involved from early on and give them an economic stake so you develop companies that people are engaged in and involved in. That would be something for entrepreneurs and communities like [SynBioBeta] to be thinking about from an early stage, as opposed to thinking about it as kind of a PR approach that comes at the very end.

Its the economy stupid, he continues. Its that classic line if people can see that their economic and social life is going to benefit from these new innovations, then theyre much more likely to be interested in supporting them and have less fear, he says.

Ibarra agrees.

There is a lot of fear around automation and AI, including in communities like ours where the fear is robots are going to come in and pick produce and there will be less jobs for our laborers, she says. But I think the opportunities deriving from biotechnology have an even greater potential. In Monterey County we have a very robust economy resulting from direct and indirect agricultural jobs, but also a significant multiplier effect. If we couple new agricultural technologies, such as automation and AI, with biotechnology in parallel, you can see this allowing communities especially rural ones to be more resilient. Its a real opportunity.

This is critical for communities like Salinas Valley, where homelessness rates in elementary schools can be as high as 50 percent. According to Ibarra, agricultural communities like Salinas are the perfect place to cultivate regenerative biotechnologies that enrich our food systems and advance public health. She and Perez imagine a future for Salinas Valley completely transformed by biotechnology rooted in racial and class equity and justice. For example, Central Coast residents could create public interest biotechnologies that emphasize community control and governance, with investment in people, infrastructure, automation, and supply-chains that extend into the community and that connect to the Valleys world-class global supply-chains. Biotechnology can also be leveraged to produce nutritious crop varieties that adapt plant morphology to make harvesting by hand easier or gene drives to combat invasive pests such as the Asian Citrus Psyllid. Animal agriculture could benefit as well, with new veterinary biotechnological tools to better care for livestock and protect them from disease. Water systems could benefit as well, from cleaning the Salinas River through mycoremediation to employing biosensors to monitor city water for pollution, pesticides, and other chemicals.

In December 2019, Golden Rice was approved for direct use in the Philippines the first Asian country to grant the controversial food approval. Some expect that the added Vitamin A present in the rice will reduce by up to 50% vitamin A deficiency, the leading cause of child mortality in the country. But, others are skeptical that the rice will be the simple solution Filipinos have been waiting for, pointing out that vitamin A deficiency is a complex problem partially rooted in culture, political economics, education, and access. In essence, Golden Rice is the perfect example of both the promise of biotechnology in agriculture and its shortcomings if we dont think critically about all sides of the issue. With up and coming companies like Pairwise Plants and others using biotechnology to produce food that is more nutritious and can be available year-round, it is critical that we heed voices like Broad, Ibarra, and Perez so that technologies that can really make a difference in how we feed the world dont meet the same fate as Golden Rice.

It is possible to feed the world with biotechnology. But its only possible if our goal isnt to feed the world, but to engage local communities, support early, equitable, and inclusive communication, and to ensure that food equity doesnt just mean that everyone can afford to buy healthy food, but that the communities producing that food have equitable economic stake. Move over, big ag its time to take biotechnology from farm to table.

Read the original post:
Why biotech's goal should not be to feed the world - SynBioBeta

The Chromatography in Pharmaceuticals and Biotechnology Market report shows a brilliant presentation of regional growth, competition and provides accurate statistics with price and gross margin and other essential factors to grow in the Chromatography in Pharmaceuticals and Biotechnology market. The Chromatography in Pharmaceuticals and Biotechnology market report digs deep into critical aspects of key subjects which help market players to make appropriate changes in their approach and help you craft better strategies. The report is made with a combination of detailed information relying upon the important data researched by our analysts.

Chromatography is a continuously evolving technique, and its success is dependent on the innovations in technology. Therefore, this report discusses the emerging trends in chromatography technology, particularly the instruments and the reagents. It also features the new developments and new product launches in the global market.

The report provides relevant patent analyses and comprehensive profiles of market players in the industry. The Industry Structure chapter focuses on the important chromatography instruments and reagent manufacturers and suppliers, their market shares and product offerings. The chapter also covers the mergers and acquisitions and any other collaborations or partnerships that happened during the evaluation period of this report that are expected to shape the industry.

BCCs new report on chromatography elaborates on the strengths, weaknesses, threats and opportunities of the global chromatography market. Any regulatory changes or new initiatives are also highlighted.

Get Sample Copy of this Report @https://www.reportsintellect.com/sample-request/698611

Chromatography in Pharmaceuticals and Biotechnology Market report provides competitive analysis which helps clients to become aware of the unique characteristics of crucial factors impacting the market competition and hence changing their growth potential by manifold. Chromatography in Pharmaceuticals and Biotechnology market report provides accurate market data, market dynamics, and key segments.

Get Discounted Report @https://www.reportsintellect.com/discount-request/698611

Table of Contents:-

Highlights of the worldwide Chromatography in Pharmaceuticals and Biotechnology Market Report:

About us:

Reports Intellect provides research reports for everything related to market research and market intelligence. We understand the importance of the market with its needs in todays competitive world.

Our team works to obtain the most authentic research reports, accompanied by perfect data figures which guarantee exceptional results for you and your company every time.

Our team is there to help you in the best possible way, whether it is the latest report from the researchers or a personalized requirement, do not hesitate to contact us.

Contact us:

[emailprotected]

PH + 1-706-996-2927

US Address:

225 Peachtree Street NE,

Suite 400,

Atlanta, GA 30303

The rest is here:
Chromatography in Pharmaceuticals and Biotechnology Expansion ( COVID 19-UPDATED ) Projected to Gain an Uptick During 2026 - Cole of Duty

The politically overhyped use of old malaria drugs in combination with COVID-19-specific candidates has been demonstrated to be dangerous, reports Nature Medicine.

In the prestigous paper Nature Medicine, cardiologists under Lior Jankelson report that patients with COVID-19 who were on a regimen of Novartis AGs generic malaria drug hydroxychloroquine and the antibiotic azithromycin experienced electrocardiogram abnormalities. Previous reports demonstrated that the same is true for chloroquine phosphate, an old malaria drug originally developed at Bayer AG. The authorsassessed 84 patients with COVID-19 treated at a centre in New York, USA.

Azithromycin in combination with antimalarial hydroxychloroquine has been touted by President Donald Trump as a possible "game changer" in COVID-19. Former BARDA head Rick Bright was fired because he resisted political interventions to push the use of chloroquine derivatives to treat COVID-19 despite scientific evidence of efficacy and safety according to current authorisation standards. Biocentury reported previously that Trumps preference for the cheap but antiquated malaria treatments looked more like political science than actually based on scientific evidence. Several clinical programmes coordinated by the WHO , the European Union, and the UK promote clinical testing of combinations with either chloroquine phosphate or hydroxychloroquine and may cause thousands of deaths unless they were not updated to include new findings.

Several reports demonstrated that both medications increase the risk of various types of cardiac rhythm abnormalities, such as QTc-interval prolongation and drug-inducedtorsades de pointes, and sudden cardiac death. The QTc interval is measured by an electrocardiogram and represents the time it takes for a heart to recharge between beats. A prolonged QTc interval puts a patient at risk for arrhythmia and sudden cardiac death.

Now, Jankelson and colleagues reviewed the charts and followed the QTc interval of 84 patients with COVID-19 on a 5-day oral regiment of hydroxychloroquine and azithromycin. The patients were, on average, 63 years of age and74% were male. After the patients were administered the drugs, the authors followed up with an electrocardiogram. They observed a prolonged QTc in most patients. The QTc was severely prolonged in 11% of the patients, which put them at high risk of arrhythmia and sudden cardiac death. Four patients in the cohort died from multiple organ failure a characteristic of septic shock without evidence of arrhythmia and without severe QTc prolongation.

Jankelson and colleagues found that most patients with COVID-19 who were treated with hydroxychloroquine and azithromycin experienced QTc prolongation. This may have been exacerbated by other pre-existing conditions and the severity of the SARS-CoV-2 infection. The authors conclude that the QTc in patients with COVID-19 who are treated with hydroxychloroquine and azithromycin should be monitored constantly, especially for patients with additional illnesses and those who are being treated with other QT-prolonging medications.

Continue reading here:
Bayer, Novartis, and Trump convicted by Nature - European Biotechnology

The ' Biotechnology Separation Systems market' research report is latest addition by Market Study Report, LLC, that elucidates relevant market and competitive insights as well as regional and consumer information. In a nutshell, the research study covers every pivotal aspect of this business sphere that influences the existing trends, profitability position, market share, market size, regional valuation, and business expansion plans of key players in the Biotechnology Separation Systems market.

The latest report on the Biotechnology Separation Systems market is a depiction of the end-to-end analysis of this business vertical, and includes quite some information about the industry, with respect to pivotal parameters such as the most recent market tendencies, present revenue, market share, market size, periodic deliverables, and profits estimations for the forecast period.

Request a sample Report of Biotechnology Separation Systems Market at:https://www.marketstudyreport.com/request-a-sample/2484141?utm_source=marketsizeforecaster.com&utm_medium=TS

A brief overview of how the Biotechnology Separation Systems market will perform over the projected timeframe has been given in the report. Also, details about the driving aspects influencing the market dynamics as well as the growth rate that the industry is expected to register over the forecast duration have been delivered. Additionally, the Biotechnology Separation Systems market report also delivers a brief of the challenges that this vertical is defined by, in conjunction with the growth opportunities that this business space is remnant of.

Main pointers highlighted in the Biotechnology Separation Systems market report:

Unveiling the Biotechnology Separation Systems market with regards to the regional terrain:

Biotechnology Separation Systems Market Segmentation: USA, Europe, Japan, China, India, South East Asia.

A gist of the details presented in the market report with regards to the major industry indicators:

Ask for Discount on Biotechnology Separation Systems Market Report at:https://www.marketstudyreport.com/check-for-discount/2484141?utm_source=marketsizeforecaster.com&utm_medium=TS

A comprehensive gist of the Biotechnology Separation Systems market with regards to the product and application spectrums:

Product landscape:

Product types: Membrane Filtration, Liquid Chromatography, Centrifuge, Electrophoresis, Flow Cytometry and Others

Key insights presented in the report:

Application landscape:

Application segmentation: Commercial and Scientific Research

Specifics provided in the report:

Other major pointers included in the report:

Some details about the competitive terrain of the Biotechnology Separation Systems market include:

Vendor base of the industry: Danaher, Sartorius Stedim Biotech, Thermo Fisher Scientific, Merck, GE Healthcare, BD, Alfa Wassermann, Agilent, Shimadzu, Sysmex, Bio-Rad Laboratories, PerkinElmer, Alfa Laval, Illumina, 3M Purification, Novasep, Hitachi Koki, Affymetrix, Waters and Repligen

Competitive analysis parameters enlisted in the report include:

The Biotechnology Separation Systems market evaluation exhibits substantial details about the aspects like market concentration ratio.

For More Details On this Report: https://www.marketstudyreport.com/reports/global-biotechnology-separation-systems-market-growth-2020-2025

Some of the Major Highlights of TOC covers:

Development Trend of Analysis of Biotechnology Separation Systems Market

Marketing Channel

Market Dynamics

Methodology/Research Approach

Related Reports:

2. Global Low-Earth Orbit Satellite Market Growth 2020-2025Low-Earth Orbit Satellite Market report characterize imperative Portion and contenders of the market regarding market estimate, volume, esteem. This report likewise covers every one of the locales and nations of the world, which demonstrates a territorial improvement status, it additionally incorporates Business Profile, Introduction, Revenue and so on.Read More: https://www.marketstudyreport.com/reports/global-low-earth-orbit-satellite-market-growth-2020-2025

Read More Reports On: https://www.marketwatch.com/press-release/military-laser-systems-market-analysis-with-key-players-applications-trends-and-forecast-to-2025-2020-04-24

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email:

Continued here:
Trends of Biotechnology Separation Systems Market Reviewed for 2020 with Industr - News.MarketSizeForecasters.com

A rating of 18 puts SAGE Therapeutics Inc (SAGE) near the bottom of the Biotechnology industry according to InvestorsObserver. SAGE Therapeutics Inc's score of 18 means it scores higher than 18% of stocks in the industry. SAGE Therapeutics Inc also received an overall rating of 35, putting it above 35% of all stocks. Biotechnology is ranked 10 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

SAGE Therapeutics Inc (SAGE) stock is trading at $38.00 as of 1:22 PM on Friday, Apr 24, a rise of $1.76, or 4.86% from the previous closing price of $36.24. The stock has traded between $35.62 and $38.03 so far today. Volume today is light. So far 545,172 shares have traded compared to average volume of 1,562,765 shares.

To see InvestorsObserver's Sentiment Score for SAGE Therapeutics Inc click here.

Go here to see the original:
Is SAGE Therapeutics Inc (SAGE) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver